share price, page-111

same as all the medical cannabis names aiming to deliver pharmaceutical grade products, predominantly to europe

while this takes time, earning income from vetinary products that require less approcals - that is happening now

added a canadian production facility - could be worth significant upgrade as it comes on

run by a hard nosed swiss female CEO who is driven to deliver

current market cap after all issues and escrow shares circa 90 mill / about half that of the ones with crops in production

does have partner with import approvals

was issue earlier this year at 68c and ipo at 20c

will be 1.00 before year end if it just keeps delivering milestones and especially with vet products now on the market